Tag: ARS

ARS Pharmaceuticals Delivers 185% Revenue Growth in Q1 2026 – Alphastreet

by PWC

May 15, 2026

AlphaStreet Newsdesk powered by AlphaStreet Intelligence SPRY|Loss Per Share $0.61 vs -$0.51 est (-19.6%)|Rev $22.7M|Internet Loss $60.6M Inventory $7.94 (-0.9%) ...

About Us
Advertise with Us
Disclaimer
Privacy Policy
DMCA
Cookie Privacy Policy
Terms and Conditions
Contact Us

No Result

View All Result

Home
Business
Economy
ESG Business
Markets
Investing
Energy
Cryptocurrency
Market Analysis

Tag: ARS

ARS Pharmaceuticals Delivers 185% Revenue Growth in Q1 2026 – Alphastreet

RECOMMENDED

Ambiq Micro Q1 2026 Deep Dive: EPS Beats by 30.6%, Revenue Up 59% – Alphastreet

Hyperscalers’ AI buildout will require massive amounts of energy. Two under-the-radar stocks will benefit

TCS Nashik case: National Commission for Women alleges zero compliance of POSH Act

1 Stock to Buy, 1 Stock to Sell This Week: Applied Materials, Alibaba | Investing.com

How Not to Provide Valuable Information – 2GreenEnergy.com

Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS (NASDAQ:ALXO)

Your Trusted Source for ESG, Corporate, and Financial Insights

Tag: ARS

ARS Pharmaceuticals Delivers 185% Revenue Growth in Q1 2026 – Alphastreet

RECOMMENDED

Ambiq Micro Q1 2026 Deep Dive: EPS Beats by 30.6%, Revenue Up 59% – Alphastreet

Hyperscalers’ AI buildout will require massive amounts of energy. Two under-the-radar stocks will benefit

TCS Nashik case: National Commission for Women alleges zero compliance of POSH Act

1 Stock to Buy, 1 Stock to Sell This Week: Applied Materials, Alibaba | Investing.com

How Not to Provide Valuable Information – 2GreenEnergy.com

Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS (NASDAQ:ALXO)

Your Trusted Source for ESG, Corporate, and Financial Insights

Follow Us